Psoriasis beyond the skin: A review of the literature on cardiometabolic and psychological co-morbidities of psoriasis

European Journal of Dermatology

Volumn 24, Issue 3, 2014, Pages 305-311

  Puig, Lluis ^a   Kirby, Brian ^b   Mallbris, Lotus ^c   Strohal, Robert ^d  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c PFIZER INC   (United States)

^d Federal Academic Teaching Hospital   (Austria)

Author keywords

Cardiovascular; Co morbidities; Psoriasis; Psychological

Indexed keywords

CARDIOVASCULAR DISEASE; COMPLICATION; CROSS-SECTIONAL STUDY; HUMAN; MENTAL DISEASE; METABOLIC DISORDER; PSORIASIS;

CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; HUMANS; MENTAL DISORDERS; METABOLIC DISEASES; PSORIASIS;

EID: 84905709664     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2014.2299     Document Type: Review

References (114)

1. Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg 2010; 29: 10-5.
2. Kimball AB, Guerin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol 2011; 25: 157-63.
3. Gerdes S, Zahl VA, Knopf H, et al. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008; 159: 1116-23.
4. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-42.
5. Prey S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 2010; 24 (Suppl 2): 23-30.
6. Gisondi P, Farina S, Giordano MV, Girolomoni G. Usefulness of the framingham risk score in patients with chronic psoriasis. Am J Cardiol 2010; 106: 1754-7.
7. Mehta NN, Krishnamoorthy P, Yu Y, et al. The impact of psoriasis on 10-year Framingham risk. J Am Acad Dermatol 2012; 67: 796-8.
8. Maradit-Kremers H, Icen M, Ernste FC, et al. Disease severity and therapy as predictors of cardiovascular risk in psoriasis: a populationbased cohort study. J Eur Acad Dermatol Venereol 2012; 26: 336-43.
9. Wakkee M, Meijer W, Neumann HA, et al. Psoriasis may not be an independent predictor for the use of cardiovascular and anti-diabetic drugs: a 5-year prevalence study. Acta Derm Venereol 2009; 89: 476-83.
10. Ahlehoff O, Skov L, Gislason G, et al. Pharmacological undertreatment of coronary risk factors in patients with psoriasis: observational study of the Danish nationwide registries. PLoS One 2012; 7: e36342.
11. Al-Mutairi N, Al-Farag S, Al-Mutairi A, Al-Shiltawy M. Comorbidities associated with psoriasis: an experience from the Middle East. J Dermatol 2010; 37: 146-55.
12. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-35.
13. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-5.
14. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-34.
15. Vena GA, Vestita M, Cassano N. Can early treatment with biologicals modify the natural history of comorbidities? Dermatol Ther 2010; 23: 181-93.
16. Bhole VM, Choi HK, Burns LC, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) 2012; 51: 552-6.
17. Armstrong AW, Harskamp CT, Ledo L, et al. Coronary artery disease in patients with psoriasis referred for coronary angiography. Am J Cardiol 2012; 109: 976-80.
18. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007; 167: 1670-5.
19. Huang YH, Yang LC, Hui RY, et al. Relationships between obesity and the clinical severity of psoriasis in Taiwan. J Eur Acad Dermatol Venereol 2010; 24: 1035-9.
20. Kim GE, Seidler E, Kimball AB. The relative impact of psoriasis and obesity on socioeconomic and medical outcomes in psoriasis patients. J Eur Acad Dermatol Venereol 2013 Jan 24. doi: 10.1111/jdv.12089.[Epub ahead of print].
21. Hossler EW, Maroon MS, Mowad CM. Gastric bypass surgery improves psoriasis. J Am Acad Dermatol 2011; 65: 198-200.
22. Farias MM, Achurra P, Boza C, et al. Psoriasis following bariatric surgery: clinical evolution and impact on quality of life on 10 patients. Obes Surg 2012; 22: 877-80.
23. Del Giglio M, Gisondi P, Tessari G, Girolomoni G.Weight reduction alone may not be sufficient to maintain disease remission in obese patients with psoriasis: a randomized, investigator-blinded study. Dermatology 2012; 224: 31-7.
24. Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011; 63: 40-6.
25. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008; 159: 895-902.
26. Chang YT, Chen TJ, Liu PC, et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm Venereol 2009; 89: 262-6.
27. Cohen AD, Dreiher J, Shapiro Y, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008; 22: 585-9.
28. Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009; 145: 379-82.
29. Azfar RS, Seminara NM, Shin DB, et al. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol 2012; 148: 995-1000.
30. Li W, Han J, Hu FB, et al. Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study. J Invest Dermatol 2012; 132: 291-8.
31. Shapiro J, Cohen AD, Weitzman D, et al. Psoriasis and cardiovascular risk factors: a case-control study on inpatients comparing psoriasis to dermatitis. J Am Acad Dermatol 2012; 66: 252-8.
32. Cheng J, Kuai D, Zhang L, et al. Psoriasis increased the risk of diabetes: a meta-analysis. Arch Dermatol Res 2012; 304: 119-25.
33. Shapiro J, Cohen AD, David M, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007; 56: 629-34.
34. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol 2008; 159: 1331-7.
35. Kimball AB, Bensimon AG, Guerin A, et al. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol 2011; 12: 51-62.
36. Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586-92.
37. Love TJ, Qureshi AA, Karlson EW, et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol 2011; 147: 419-24.
38. Mebazaa A, El Asmi M, Zidi W, et al. Metabolic syndrome in Tunisian psoriatic patients: prevalence and determinants. J Eur Acad Dermatol Venereol 2011; 25: 705-9.
39. Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol 2010; 76: 662-5.
40. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
41. Augustin M, Reich K, Glaeske G, et al. Co-morbidity and agerelated prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90: 147-51.
42. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012; 132: 556-62.
43. Altobelli E, Petrocelli R, Maccarone M, et al. Risk factors of hypertension, diabetes and obesity in Italian psoriasis patients: a survey on socio-demographic characteristics, smoking habits and alcohol consumption. Eur J Dermatol 2009; 19: 252-6.
44. Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol 2010; 90: 23-6.
45. Armesto S, Coto-Segura P, Osuna CG, et al. Psoriasis and hypertension: a case-control study. J Eur Acad Dermatol Venereol 2012; 26: 785-8.
46. Armstrong AW, Lin SW, Chambers CJ, et al. Psoriasis and hypertension severity: results from a case-control study. PLoS One 2011; 6: e18227.
47. Dreiher J, Weitzman D, Davidovici B, et al. Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol 2008; 88: 561-5.
48. Warnecke C, Manousaridis I, Herr R, et al. Cardiovascular and metabolic risk profile in German patients with moderate and severe psoriasis: a case control study. Eur J Dermatol 2011; 21: 761-70.
49. Xiao J, Chen LH, Tu YT, et al. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol 2009; 23: 1311-5.
50. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-8.
51. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011; 270: 147-57.
52. Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145: 700-3.
53. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-6.
54. Mehta NN, Yu Y, Pinnelas R et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011; 124: 775.e1-6.
55. Schmitt J, Ford DE. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. J Eur Acad Dermatol Venereol 2010; 24: 885-92.
56. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000-6.
57. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
58. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009; 129: 2411-8.
59. Li WQ, Han JL, Manson JE, et al. Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. Br J Dermatol 2012; 166: 811-8.
60. Chiang CH, Huang CC, Chan WL, et al. Psoriasis and increased risk of ischemic stroke in Taiwan: a nationwide study. J Dermatol 2012; 39: 279-81.
61. Ahlehoff O, Gislason GH, Jorgensen CH, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J 2012; 33: 2054-64.
62. Xu T, Zhang YH. Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. Br J Dermatol 2012; 167: 1345-50.
63. Au SC, Goldminz AM, Loo DS, et al. Association between pediatric psoriasis and the metabolic syndrome. J Am Acad Dermatol 2012; 66: 1012-3.
64. Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633-6.
65. Koebnick C, Black MH, Smith N, et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr 2011; 159: 577-83.
66. Ozden MG, Tekin NS, Gurer MA, et al. Environmental risk factors in pediatric psoriasis: a multicenter case-control study. Pediatr Dermatol 2011; 28: 306-12.
67. Bryld LE, Sorensen TI, Andersen KK, et al. High body mass index in adolescent girls precedes psoriasis hospitalization. Acta Derm Venereol 2010; 90: 488-93.
68. Aronson PJ, Malick F. Towards rational treatment of severe psoriasis in alcoholics: report of two cases. J Drugs Dermatol 2010; 9: 405-8.
69. Biljan D, Laufer D, Filaković P, et al. Psoriasis, mental disorders and stress. Coll Antropol 2009; 33: 889-92.
70. McAleer MA, Mason DL, Cunningham S, et al. Alcohol misuse in patients with psoriasis: identification and relationship to disease severity and psychological distress. Br J Dermatol 2011; 164: 1256-61.
71. Gerdes S, Zahl VA, Weichenthal M, Mrowietz U. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology 2010; 220: 38-43.
72. Qureshi AA, Dominguez PL, Choi HK, et al. Alcohol intake and risk of incident psoriasis in US women: a prospective study. Arch Dermatol 2010; 146: 1364-9.
73. Tobin AM, Higgins EM, Noris S, et al. Prevalence of psoriasis in patients with alcoholic liver disease. Clin Exp Dermatol 2009; 34: 698-701.
74. Jiamton S, Suthipinittharm P, Kulthanan K, et al. Clinical characteristics of Thai patients with psoriasis. J Med Assoc Thai 2012; 95: 795-801.
75. Bo K, Thoresen M, Dalgard F. Smokers report more psoriasis, but not atopic dermatitis or hand eczema: results from a Norwegian population survey among adults. Dermatology 2008; 216: 40-5.
76. Li W, Han J, Choi HK, Qureshi AA. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol 2012; 175: 402-13.
77. Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med 2007; 120: 953-9.
78. Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143: 1559-65.
79. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-7.
80. Tey HL, Ee HL, Tan AS, et al. Risk factors associated with having psoriatic arthritis in patients with cutaneous psoriasis. J Dermatol 2010; 37: 426-30.
81. Eder L, Law T, Chandran V, et al. Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res (Hoboken) 2011; 63: 1091-7.
82. Davidsson S, Blomqvist K, Molin L, et al. Lifestyle of Nordic people with psoriasis. Int J Dermatol 2005; 44: 378-83.
83. Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology 2006; 212: 123-7.
84. Altobelli E, Maccarone M, Petrocelli R, et al. Analysis of health care and actual needs of patients with psoriasis: a survey on the Italian population. BMC Public Health 2007; 7: 59.
85. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 2008; 7: 373-7.
86. Husted JA, Thavaneswaran A, Chandran V, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken) 2011; 63: 1729-35.
87. Dauden E, Griffiths CE, Ortonne JP, et al. Improvements in patientreported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009; 23: 1374-82.
88. Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891-5.
89. Masmoudi J, Maalej I, Masmoudi A, et al. Alexithymia and psoriasis: a case-control study of 53 patients. Encephale 2009; 35: 10-7.
90. Chen SJ, Chao YL, Chen CY, et al. Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study. Br J Psychiatry 2012; 200: 374-80.
91. Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology 2007; 215: 17-27.
92. Sampogna F, Chren MM, Melchi CF, et al. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol 2006; 154: 325-31.
93. Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol 2008; 159: 704-10.
94. Smith CH, Barker JN. Psoriasis and its management. BMJ 2006; 333: 380-4.
95. Kimball AB, Wu EQ, Guerin A et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol 2012; 67: 651-7.e1-2.
96. Bilgic A, Bilgic O, Akiş HK, et al. Psychiatric symptoms and healthrelated quality of life in children and adolescents with psoriasis. Pediatr Dermatol 2010; 27: 614-7.
97. Seyhan M, Coşkun BK, Saǧlam H, et al. Psoriasis in childhood and adolescence: evaluation of demographic and clinical features. Pediatr Int 2006; 48: 525-30.
98. Varni JW, Globe DR, Gandra SR, et al. Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases. Eur J Pediatr 2012; 171: 485-92.
99. Mercan S, Altunay IK, Demir B, et al. Sexual dysfunctions in patients with neurodermatitis and psoriasis. J Sex Marital Ther 2008; 34: 160-8.
100. Sampogna F, Gisondi P, Tabolli S, et al. Impairment of sexual life in patients with psoriasis. Dermatology 2007; 214: 144-50.
101. Goulding JM, Price CL, Defty CL, et al. Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need, and a chance to intervene. Br J Dermatol 2011; 164: 103-9.
102. Turel Ermertcan A, Temeltaş G, Deveci A, et al. Sexual dysfunction in patients with psoriasis. J Dermatol 2006; 33: 772-8.
103. Al-Mazeedi K, El-Shazly M, Al-Ajmi HS. Impact of psoriasis on quality of life in Kuwait. Int J Dermatol 2006; 45: 418-24.
104. Meeuwis KA, de Hullu JA, van de Nieuwenhof HP, et al. Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol 2011; 164: 1247-55.
105. Yang YW, Kang JH, Lin HC. Increased risk of psoriasis following obstructive sleep apnea: a longitudinal population-based study. Sleep Med 2012; 13: 285-9.
106. Thorburn PT, Riha RL. Skin disorders and sleep in adults: where is the evidence? Sleep Med Rev 2010; 14: 351-8.
107. Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol 2011; 165: 1066-73.
108. Gerdes S, Mrowietz U. Impact of comorbidities on the management of psoriasis. Curr Probl Dermatol 2009; 38: 21-36.
109. Hamminga EA, van der Lely AJ, Neumann HA, et al. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses 2006; 67: 768-73.
110. Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006; 298: 309-19.
111. Wakkee M, Thio HB, Prens EP, et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007; 190: 1-9.
112. Armstrong AW, Armstrong EJ, Fuller EN, et al. Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. Br J Dermatol 2011; 165: 1162-8.
113. Bhosle MJ, Kulkarni A, Feldman SR, et al. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006; 4: 35.
114. Hayes J, Koo J. Psoriasis: depression, anxiety, smoking, and drinking habits. Dermatol Ther 2010; 23: 174-80.